|
US8871908B2
(en)
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
TWI589592B
(zh)
|
2011-11-17 |
2017-07-01 |
輝瑞股份有限公司 |
胞毒性肽類以及其抗體藥物共軛體
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
AU2012356894B2
(en)
*
|
2011-12-23 |
2018-01-18 |
Araris Biotech Ltd. |
Enzymatic conjugation of polypeptides
|
|
WO2014009426A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014047357A1
(en)
*
|
2012-09-21 |
2014-03-27 |
The Regents Of The University Of California |
Modified fc polypeptides, fc conjugates, and methods of use thereof
|
|
ES2656298T3
(es)
|
2012-11-05 |
2018-02-26 |
Pfizer Inc. |
Análogos de ayustoestatina
|
|
CA2890571A1
(en)
|
2012-11-07 |
2014-05-15 |
Kenneth G. Geles |
Anti-notch3 antibodies and antibody-drug conjugates
|
|
EP2916872B1
(en)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014093379A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
CN105209033B
(zh)
|
2013-03-14 |
2018-09-18 |
马萨诸塞大学 |
抑制白内障和老花眼的方法
|
|
US9522876B2
(en)
|
2013-03-15 |
2016-12-20 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
FR3005051A1
(fr)
*
|
2013-04-25 |
2014-10-31 |
Pf Medicament |
Derives de la dolastatine 10 et d'auristatines
|
|
EP2992331A4
(en)
|
2013-04-30 |
2017-03-29 |
Université de Montréal |
Novel biomarkers for acute myeloid leukemia
|
|
ES2759503T3
(es)
|
2013-05-02 |
2020-05-11 |
Glykos Finland Oy |
Conjugados de una glicoproteína o un glicano con una carga útil tóxica
|
|
BR112015030514A2
(pt)
*
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
WO2014202773A1
(en)
*
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
JP6744212B2
(ja)
*
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
ポリペプチドの酵素的結合
|
|
EP2818867A1
(en)
|
2013-06-27 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies conjugated to at least one nucleic acid molecule and their use in multiplex immuno-detection assays
|
|
EP3016973A1
(en)
|
2013-07-05 |
2016-05-11 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
BR112016000585A2
(pt)
|
2013-07-11 |
2018-03-20 |
Novartis Ag |
modificações quimioenzimáticas sítio-específicas de proteína
|
|
EP3027224B1
(en)
|
2013-07-31 |
2020-06-03 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates using transglutaminase
|
|
KR101809072B1
(ko)
|
2013-08-02 |
2017-12-14 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
|
BR112016010051A2
(pt)
|
2013-11-04 |
2017-12-05 |
Pfizer |
?conjugados de anticorpo-fármaco anti-efna4?
|
|
MX2016008355A
(es)
|
2013-12-23 |
2016-10-28 |
Zymeworks Inc |
Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
|
|
WO2015097267A1
(en)
*
|
2013-12-23 |
2015-07-02 |
Covalab |
mTG SUBSTRATES FOR COVALENT CONJUGATION OF COMPOUNDS
|
|
ES2916722T3
(es)
|
2013-12-27 |
2022-07-05 |
Zymeworks Inc |
Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
|
|
CA2937731C
(en)
|
2014-01-27 |
2019-09-24 |
Pfizer Inc. |
Bifunctional cytotoxic agents
|
|
CN106456798B
(zh)
|
2014-04-25 |
2021-02-12 |
瑞纳神经科学公司 |
具有高药物负载的抗体-药物缀合物
|
|
EP3134124B1
(en)
|
2014-04-25 |
2019-02-20 |
Pierre Fabre Medicament |
Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
|
|
CN106470708B
(zh)
|
2014-04-25 |
2019-12-31 |
皮埃尔法布雷医药公司 |
抗体-药物-缀合物和其用于治疗癌症的用途
|
|
EP3137114B8
(en)
|
2014-04-30 |
2021-08-04 |
Pfizer Inc. |
Anti-ptk7 antibody-drug conjugates
|
|
RU2728235C2
(ru)
|
2014-06-12 |
2020-07-28 |
СиЭсПиСи ДОФЕН КОРПОРЕЙШН |
Конъюгат антитела и лекарственного средства, композиции на его основе и способы их получения
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
KR102051503B1
(ko)
*
|
2014-08-28 |
2019-12-03 |
화이자 인코포레이티드 |
항체 약물 접합체에 사용하기 위한 안정성-조정 링커
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
US11054425B2
(en)
|
2014-12-19 |
2021-07-06 |
Roche Sequencing Solutions, Inc. |
System and method for identification and characterization of transglutaminase species
|
|
CN107406483B
(zh)
*
|
2014-12-19 |
2022-02-22 |
豪夫迈·罗氏有限公司 |
微生物转谷氨酰胺酶，其底物和其使用方法
|
|
CA2971246C
(en)
|
2014-12-19 |
2020-07-14 |
F. Hoffmann-La Roche Ag |
Identification of transglutaminase substrates and uses therefor
|
|
ES2736106T3
(es)
*
|
2015-03-10 |
2019-12-26 |
Bristol Myers Squibb Co |
Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
|
|
WO2016151432A1
(en)
|
2015-03-20 |
2016-09-29 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the cti pharmacophore
|
|
IL310723A
(en)
|
2015-04-13 |
2024-04-01 |
Pfizer |
Therapeutic antibodies and their uses
|
|
WO2016170447A1
(en)
|
2015-04-24 |
2016-10-27 |
Rinat Neuroscience Corp. |
Recombinant microbial transglutaminases
|
|
CA2994741A1
(en)
|
2015-08-07 |
2017-02-16 |
Merck Patent Gmbh |
A transglutamine tag for efficient site-specific bioconjugation
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
|
CN108348494A
(zh)
*
|
2015-11-13 |
2018-07-31 |
马萨诸塞大学 |
用于抑制白内障和老花眼的含peg的双官能分子
|
|
US10689458B2
(en)
|
2015-11-30 |
2020-06-23 |
Pfizer Inc. |
Site specific HER2 antibody drug conjugates
|
|
TWI703160B
(zh)
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR102943992B1
(ko)
|
2015-12-15 |
2026-03-25 |
에프. 호프만-라 로슈 아게 |
트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인
|
|
MX2018007451A
(es)
*
|
2015-12-18 |
2018-11-09 |
Eisai R&D Man Co Ltd |
Inmunoglobulinas conjugadas con lisina c-terminal.
|
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
|
CN109219618B
(zh)
|
2016-01-21 |
2022-08-09 |
辉瑞大药厂 |
针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
|
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
|
US11786603B2
(en)
|
2016-02-26 |
2023-10-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
WO2017162678A1
(en)
|
2016-03-22 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Humanized anti-claudin-1 antibodies and uses thereof
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
ES2909833T3
(es)
|
2016-05-11 |
2022-05-10 |
Cytiva Bioprocess R & D Ab |
Método de limpieza y/o desinfección de una matriz de separación
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
JP7106187B2
(ja)
|
2016-05-11 |
2022-07-26 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを保存する方法
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
ES2874974T3
(es)
|
2016-05-11 |
2021-11-05 |
Cytiva Bioprocess R & D Ab |
Matriz de separación
|
|
CA3026991A1
(en)
|
2016-06-10 |
2017-12-14 |
Eisai R&D Management Co., Ltd. |
Lysine conjugated immunoglobulins
|
|
EP3272864A1
(en)
|
2016-07-20 |
2018-01-24 |
Paul Scherrer Institut |
Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
|
|
EP3493853A1
(en)
|
2016-08-03 |
2019-06-12 |
Pfizer Inc |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
|
ES2902179T3
(es)
|
2016-08-19 |
2022-03-25 |
Bristol Myers Squibb Co |
Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
|
|
PL3512882T3
(pl)
|
2016-09-14 |
2022-01-10 |
Merck Patent Gmbh |
Przeciwciała anty-c-met i ich koniugaty przeciwciał z lekami do efektywnej inhibicji nowotworów
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
EP3525828B1
(en)
*
|
2016-10-17 |
2024-12-25 |
Pfizer Inc. |
Anti-edb antibodies and antibody-drug conjugates
|
|
WO2018075842A1
(en)
|
2016-10-20 |
2018-04-26 |
Bristol-Myers Squibb Company |
Condensed benzodiazepine derivatives and conjugates made therefrom
|
|
CN110121508A
(zh)
|
2016-10-25 |
2019-08-13 |
法国国家健康和医学研究院 |
与cd160跨膜同种型结合的单克隆抗体
|
|
EP3541830A1
(en)
|
2016-11-17 |
2019-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
|
WO2018138591A1
(en)
|
2017-01-24 |
2018-08-02 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
|
KR20190124753A
(ko)
|
2017-03-03 |
2019-11-05 |
리나트 뉴로사이언스 코프. |
항-gitr 항체 및 이의 사용 방법
|
|
KR102808275B1
(ko)
|
2017-04-14 |
2025-05-20 |
탈락 테라퓨틱스, 인크. |
면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
|
|
US11939385B2
(en)
|
2017-05-16 |
2024-03-26 |
ALX Oncology Inc. |
Activatable antibodies and methods of use thereof
|
|
PE20242042A1
(es)
|
2017-06-02 |
2024-10-10 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
CA3177215A1
(en)
*
|
2017-09-19 |
2019-03-28 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
MX2020004381A
(es)
*
|
2017-10-27 |
2020-08-20 |
Pfizer |
Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
TWI878213B
(zh)
|
2018-02-01 |
2025-04-01 |
美商輝瑞大藥廠 |
對cd70具特異性抗體及其用途
|
|
TW201936633A
(zh)
|
2018-02-01 |
2019-09-16 |
美商輝瑞大藥廠 |
標靶至cd70的嵌合抗原受體
|
|
CN111788222A
(zh)
|
2018-02-27 |
2020-10-16 |
辉瑞大药厂 |
抗体纯化
|
|
US12492230B2
(en)
|
2018-03-16 |
2025-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin V and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US12098179B2
(en)
|
2018-03-16 |
2024-09-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
EP3768324B1
(en)
|
2018-03-22 |
2025-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
DK3797121T3
(da)
|
2018-05-23 |
2024-07-08 |
Pfizer |
Antistoffer, der er specifikke for CD3, og anvendelser deraf
|
|
BR112020022595A2
(pt)
|
2018-05-23 |
2021-02-09 |
Pfizer Inc. |
anticorpos específicos para gucy2c e usos dos mesmos
|
|
SG11202011739SA
(en)
|
2018-05-29 |
2020-12-30 |
Bristol Myers Squibb Co |
Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
|
|
EP3810640A1
(en)
|
2018-06-25 |
2021-04-28 |
University of Washington |
De novo design of potent and selective interleukin mimetics
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
JP2022511390A
(ja)
|
2018-11-20 |
2022-01-31 |
ユニバーシティ オブ ワシントン |
分割インターロイキン模倣体およびその使用
|
|
KR102861586B1
(ko)
|
2018-11-30 |
2025-09-17 |
브리스톨-마이어스 스큅 컴퍼니 |
글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
|
|
JP7514836B2
(ja)
*
|
2018-12-12 |
2024-07-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
|
|
JP7609775B2
(ja)
|
2018-12-14 |
2025-01-07 |
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） |
単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
|
|
EP3898698B1
(en)
|
2018-12-21 |
2026-04-01 |
Multitude Therapeutics Co., Ltd. |
Chimeric antigen receptor specific to muc18
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
JP7599425B2
(ja)
*
|
2019-01-09 |
2024-12-13 |
ヴェクト－オール |
トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用
|
|
KR20220144753A
(ko)
*
|
2019-03-19 |
2022-10-27 |
폴 슈레 앙스띠뛰 |
글리신 기반 링커를 사용한 트랜스글루타미나제 컨쥬게이션 방법
|
|
US20220251232A1
(en)
|
2019-05-20 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
|
JP7590354B2
(ja)
*
|
2019-06-10 |
2024-11-26 |
ストロ バイオファーマ インコーポレーテッド |
免疫調節物質抗体薬物コンジュゲートおよびその使用
|
|
CN114269749B
(zh)
|
2019-06-10 |
2024-10-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
IL293375A
(en)
*
|
2019-12-03 |
2022-07-01 |
Debiopharm Res & Manufacturing S A |
reactive couplings
|
|
US12577324B2
(en)
|
2019-12-09 |
2026-03-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity to HER4 and uses thereof
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
|
US12594302B2
(en)
|
2020-05-20 |
2026-04-07 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
JP7858550B2
(ja)
|
2020-05-26 |
2026-05-14 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
|
|
CA3189590A1
(en)
|
2020-07-17 |
2022-01-20 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
MX2023002974A
(es)
|
2020-09-14 |
2023-05-25 |
Regeneron Pharma |
Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos.
|
|
KR20230069211A
(ko)
*
|
2020-09-18 |
2023-05-18 |
아라리스 바이오테크 아게 |
아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법
|
|
WO2022071291A1
(ja)
*
|
2020-09-29 |
2022-04-07 |
出光興産株式会社 |
ペプチドタグおよびそれを含むタグ付加タンパク質
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
WO2022084560A1
(en)
|
2020-10-25 |
2022-04-28 |
Araris Biotech Ag |
Means and methods for producing antibody-linker conjugates
|
|
AU2021377185A1
(en)
|
2020-11-10 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Selenium antibody conjugates
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
CN118878694A
(zh)
|
2020-11-23 |
2024-11-01 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
US20240131138A1
(en)
|
2020-12-23 |
2024-04-25 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
CN114685657B
(zh)
|
2020-12-31 |
2024-08-16 |
康诺亚生物医药科技（成都）有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
|
EP4284832A1
(en)
|
2021-01-29 |
2023-12-06 |
(INSERM) Institut National de la Santé et de la Recherche Médicale |
Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
|
|
FR3120877B1
(fr)
|
2021-03-19 |
2025-03-14 |
Univ Toulouse 3 Paul Sabatier |
Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
FR3120865B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
FR3120866B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
|
|
JP2024512567A
(ja)
|
2021-03-23 |
2024-03-19 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
Ｔ細胞リンパ腫の診断および治療方法
|
|
JP2024511465A
(ja)
|
2021-03-26 |
2024-03-13 |
イナート・ファルマ・ソシエテ・アノニム |
Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
|
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
|
US20240368605A1
(en)
|
2021-04-19 |
2024-11-07 |
Institut National de la Santé et de la Recherche Médicale |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
|
AU2022270880A1
(en)
|
2021-05-03 |
2023-09-28 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
MX2023014647A
(es)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
Proteinas de union a nkp46 multiespecificas.
|
|
WO2022263451A1
(en)
|
2021-06-15 |
2022-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes
|
|
KR20240038928A
(ko)
|
2021-07-28 |
2024-03-26 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질-항바이러스 화합물 접합체
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
EP4422695A1
(en)
|
2021-10-25 |
2024-09-04 |
Araris Biotech AG |
Methods for producing antibody-linker conjugates
|
|
EP4433504A1
(en)
|
2021-11-17 |
2024-09-25 |
Institut National de la Santé et de la Recherche Médicale |
Universal sarbecovirus vaccines
|
|
EP4448095A1
(en)
|
2021-12-14 |
2024-10-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
EP4201956A1
(en)
*
|
2021-12-23 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Kutzneria albida (kalbtg) transglutaminase used for antibody conjugations
|
|
CA3242639A1
(en)
|
2022-01-14 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin A derivatives and their antibody-drug conjugates
|
|
EP4472740A1
(en)
|
2022-01-31 |
2024-12-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
CN118742328A
(zh)
|
2022-02-22 |
2024-10-01 |
阿拉里斯生物技术股份公司 |
包含两个或更多个有效载荷的肽接头
|
|
AU2023227442A1
(en)
|
2022-03-03 |
2024-09-12 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
|
AU2023231305A1
(en)
|
2022-03-11 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof
|
|
JP2025514669A
(ja)
|
2022-04-11 |
2025-05-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍の診断及び処置のための方法
|
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
CN119233994A
(zh)
|
2022-05-25 |
2024-12-31 |
先天制药公司 |
Nectin-4结合剂
|
|
US20230408497A1
(en)
|
2022-06-20 |
2023-12-21 |
Sysmex Corporation |
Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
|
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
|
EP4558823A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
|
KR20250054842A
(ko)
|
2022-07-29 |
2025-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
|
|
JP2025531832A
(ja)
|
2022-09-08 |
2025-09-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
|
|
FR3139821B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations
|
|
FR3139820B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
|
|
EP4598953A1
(en)
|
2022-10-05 |
2025-08-13 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
CN120659785A
(zh)
|
2022-11-30 |
2025-09-16 |
里珍纳龙药品有限公司 |
Tlr7激动剂及其抗体-药物缀合物
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
WO2024236156A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
AU2024276787A1
(en)
|
2023-05-23 |
2026-01-15 |
Allygen Group |
Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
|
|
IL325400A
(en)
|
2023-07-10 |
2026-02-01 |
Regeneron Pharma |
Anti-human CACNG1 antibody-drug conjugates and their uses
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
WO2025188693A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Bicyclic tlr7 agonists and uses thereof
|
|
WO2025188694A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Tricyclic tlr7 agonists and uses thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025238052A1
(en)
|
2024-05-15 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
|
|
WO2026013234A1
(en)
|
2024-07-10 |
2026-01-15 |
Araris Biotech Ag |
Triple-payload antibody-drug conjugates (adcs)
|